tiprankstipranks
Trending News
More News >
Charmacy Pharmaceutical Co., Ltd. Class H (HK:2289)
:2289
Hong Kong Market

Charmacy Pharmaceutical Co., Ltd. Class H (2289) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Charmacy Pharmaceutical Co., Ltd. Class H has a market cap or net worth of HK$756.00M. The enterprise value is HK$1.83B.
Market CapHK$756.00M
Enterprise ValueHK$1.83B

Share Statistics

Charmacy Pharmaceutical Co., Ltd. Class H has 108,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding108,000,000
Owned by Insiders
Owned by Institutions

Financial Efficiency

Charmacy Pharmaceutical Co., Ltd. Class H’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 2.37%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)2.37%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee5.24M
Profits Per Employee62.91K
Employee Count847
Asset Turnover1.28
Inventory Turnover6.27

Valuation Ratios

The current PE Ratio of Charmacy Pharmaceutical Co., Ltd. Class H is 18.65. Charmacy Pharmaceutical Co., Ltd. Class H’s PEG ratio is 6.29.
PE Ratio18.65
PS Ratio0.00
PB Ratio1.12
Price to Fair Value1.61
Price to FCF-10.99
Price to Operating Cash Flow-16.31
PEG Ratio6.29

Income Statement

In the last 12 months, Charmacy Pharmaceutical Co., Ltd. Class H had revenue of 4.44B and earned 53.28M in profits. Earnings per share was 0.54.
Revenue4.44B
Gross Profit324.76M
Operating Income73.25M
Pretax Income71.19M
Net Income53.28M
EBITDA166.95M
Earnings Per Share (EPS)0.54

Cash Flow

In the last 12 months, operating cash flow was 106.04M and capital expenditures -9.88M, giving a free cash flow of 90.31M billion.
Operating Cash Flow106.04M
Free Cash Flow90.31M
Free Cash Flow per Share0.84

Dividends & Yields

Charmacy Pharmaceutical Co., Ltd. Class H pays an annual dividend of HK$0.478, resulting in a dividend yield of 6.99%
Dividend Per ShareHK$0.478
Dividend Yield6.99%
Payout Ratio89.51%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.44
52-Week Price Change-13.15%
50-Day Moving Average7.20
200-Day Moving Average7.89
Relative Strength Index (RSI)43.91
Average Volume (3m)950.00

Important Dates

Charmacy Pharmaceutical Co., Ltd. Class H upcoming earnings date is Aug 25, 2025, TBA Not Confirmed.
Last Earnings DateMar 28, 2025
Next Earnings DateAug 25, 2025
Ex-Dividend DateMay 26, 2025

Financial Position

Charmacy Pharmaceutical Co., Ltd. Class H as a current ratio of 1.09, with Debt / Equity ratio of 274.30%
Current Ratio1.09
Quick Ratio0.85
Debt to Market Cap1.66
Net Debt to EBITDA6.79
Interest Coverage Ratio1.21

Taxes

In the past 12 months, Charmacy Pharmaceutical Co., Ltd. Class H has paid 17.91M in taxes.
Income Tax17.91M
Effective Tax Rate0.25

Enterprise Valuation

Charmacy Pharmaceutical Co., Ltd. Class H EV to EBITDA ratio is 12.74, with an EV/FCF ratio of 23.56.
EV to Sales0.48
EV to EBITDA12.74
EV to Free Cash Flow23.56
EV to Operating Cash Flow20.07

Balance Sheet

Charmacy Pharmaceutical Co., Ltd. Class H has HK$563.15M in cash and marketable securities with ¥1.70B in debt, giving a net cash position of HK$1.13B billion.
Cash & Marketable SecuritiesHK$563.15M
Total Debt¥1.70B
Net CashHK$1.13B
Net Cash Per ShareHK$10.50
Tangible Book Value Per ShareHK$5.00

Margins

Gross margin is 7.02%, with operating margin of 1.65%, and net profit margin of 1.20%.
Gross Margin7.02%
Operating Margin1.65%
Pretax Margin1.61%
Net Profit Margin1.20%
EBITDA Margin3.76%
EBIT Margin2.97%

Analyst Forecast

The average price target for Charmacy Pharmaceutical Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart Score5
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis